Full Breakdown
Medline Inc. Achieves Record IPO in 2025
12/19/2025, 9:36:14 PM
Medline's Historic Market Debut
Medline Inc., a leading U.S. medical supplies manufacturer and distributor, successfully launched its initial public offering (IPO) on December 17, 2025, raising $6.26 billion. This IPO marks the largest globally for the year and the biggest U.S. listing since Rivian Automotive's $13.7 billion offering in 2021. Medline's shares opened at $35, significantly above the IPO price of $29, and closed at $41, resulting in a market capitalization of approximately $54 billion.
The company sold 216 million shares, exceeding its initial plan to offer 179 million shares priced between $26 and $30. The upsized offering reflects strong investor interest, particularly in Medline's robust business model, which includes a diverse portfolio of over 335,000 medical-surgical products.
Background and Context
Founded in 1966 by brothers Jon and Jim Mills, Medline was privately owned until 2021 when it was acquired by private equity firms Blackstone, Carlyle Group, and Hellman & Friedman for $34 billion. This acquisition was one of the largest leveraged buyouts in history. The IPO follows a period of significant market volatility, including the impact of President Donald Trump's tariffs and the longest U.S. government shutdown, which delayed Medline's public listing.
Financial Performance and Business Model
For the nine months ending September 2025, Medline reported net income of $977 million on revenues of $20.6 billion, up from $911 million on $18.7 billion in the same period the previous year. The company’s business model focuses on both manufacturing and distributing medical supplies, allowing it to capture a larger share of revenue compared to traditional distributors. Medline's CEO, Jim Boyle, likened the company's aspirations to those of Costco, emphasizing a commitment to customer value and operational efficiency.
Official Statements & Responses
In a statement regarding the IPO, Jim Boyle remarked, “We’re going to run the business exactly the same way we ran it yesterday. It (the IPO) just allows us to buy down debt and amplify our voice.” This sentiment reflects Medline's strategy to leverage its public status for growth while maintaining its operational integrity.
Criticism & Opposition
Despite the positive reception of the IPO, analysts have raised concerns about Medline's substantial debt load, which is expected to remain high even after using IPO proceeds to reduce it. Additionally, the company faces potential tariff costs estimated between $325 million and $375 million for 2025, which could impact profitability.
What's Next
The successful IPO is anticipated to encourage more private equity-backed firms to pursue public listings, potentially revitalizing the IPO market in 2026. Analysts are optimistic about Medline's future, given its established market position and the resilience of the healthcare sector.
Verbatim Quotes
- “We are the largest company you've never heard of, and we happen to be everywhere.” — Jim Boyle, CEO of Medline
- “This is a very different profile than the typical growth IPO — Medline is profitable, cash-generative, and well understood, which resonates in the current market,” — Jeff Zell, Senior Research Analyst at IPO Boutique
Medline's IPO not only signifies a pivotal moment for the company but also reflects broader trends in the U.S. IPO market, showcasing resilience amid economic challenges.
